Protocol Page


	Study ID (Protocol Number)
	CA216-002


	STUDY LOCATIONS*
	Dana Farber Cancer Institute Boston, MA 02215 Recruiting	The University Of Texas Md Anderson Cancer Center Houston, TX 77030 Recruiting
	Memorial Sloan Kettering Cancer Center New York, NY 10065 Recruiting
	*Not all study site locations may be listed - please check back soon for updated information. For more information regarding other participating countries, please visit clinicaltrials.gov.

	STUDY NAME
	Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
	STUDY OVERVIEW
	The purpose of this study is to identify a safe and tolerable dose of BMS-906024, either alone or in combination with Dexamethasone in subjects with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma who no longer respond to or have relapsed from standard therapies

The study information provided here is a portion of what is available on ClinicalTrials.gov. Please visit ClinicalTrials.gov for complete information about this and other clinical studies.